Compare Orchid Chemicals with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DIVIS LABORATORIES - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DIVIS LABORATORIES ORCHID PHARMA LTD/
DIVIS LABORATORIES
 
P/E (TTM) x -0.5 34.2 - View Chart
P/BV x 0.1 6.4 1.9% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ORCHID PHARMA LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DIVIS LABORATORIES
Mar-19
ORCHID PHARMA LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1941,639 11.8%   
Low Rs351,115 3.1%   
Sales per share (Unadj.) Rs276.5186.3 148.4%  
Earnings per share (Unadj.) Rs-79.251.0 -155.4%  
Cash flow per share (Unadj.) Rs-43.557.3 -75.8%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs53.9261.8 20.6%  
Shares outstanding (eoy) m70.45265.47 26.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.47.4 5.6%   
Avg P/E ratio x-1.427.0 -5.3%  
P/CF ratio (eoy) x-2.624.0 -11.0%  
Price / Book Value ratio x2.15.3 40.4%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m8,067365,592 2.2%   
No. of employees `0002.811.8 23.6%   
Total wages/salary Rs m2,5275,423 46.6%   
Avg. sales/employee Rs Th6,956.14,175.1 166.6%   
Avg. wages/employee Rs Th902.5457.7 197.2%   
Avg. net profit/employee Rs Th-1,993.01,141.8 -174.5%   
INCOME DATA
Net Sales Rs m19,47749,463 39.4%  
Other income Rs m4071,556 26.2%   
Total revenues Rs m19,88451,019 39.0%   
Gross profit Rs m1,10318,718 5.9%  
Depreciation Rs m2,5191,689 149.2%   
Interest Rs m5,22735 14,933.7%   
Profit before tax Rs m-6,23618,551 -33.6%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,023 -2.5%   
Profit after tax Rs m-5,58013,527 -41.3%  
Gross profit margin %5.737.8 15.0%  
Effective tax rate %2.027.1 7.4%   
Net profit margin %-28.727.3 -104.8%  
BALANCE SHEET DATA
Current assets Rs m11,01446,501 23.7%   
Current liabilities Rs m32,0608,468 378.6%   
Net working cap to sales %-108.176.9 -140.5%  
Current ratio x0.35.5 6.3%  
Inventory Days Days95131 72.5%  
Debtors Days Days3486 39.1%  
Net fixed assets Rs m29,44025,797 114.1%   
Share capital Rs m705531 132.7%   
"Free" reserves Rs m2,04368,962 3.0%   
Net worth Rs m3,80069,493 5.5%   
Long term debt Rs m9,0180-   
Total assets Rs m46,51080,383 57.9%  
Interest coverage x-0.2531.0 -0.0%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.40.6 68.1%   
Return on assets %-0.816.9 -4.5%  
Return on equity %-146.919.5 -754.4%  
Return on capital %-3.726.7 -14.0%  
Exports to sales %37.90-   
Imports to sales %22.624.6 91.8%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,40612,187 36.2%   
Fx inflow Rs m7,51341,238 18.2%   
Fx outflow Rs m5,64912,405 45.5%   
Net fx Rs m1,86528,833 6.5%   
CASH FLOW
From Operations Rs m1,6829,543 17.6%  
From Investments Rs m-9,860-6,854 143.9%  
From Financial Activity Rs m6,644-2,459 -270.1%  
Net Cashflow Rs m-1,535230 -668.6%  

Share Holding

Indian Promoters % 32.3 52.0 62.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 11.8 39.0%  
FIIs % 3.3 19.0 17.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.2 321.5%  
Shareholders   84,811 31,796 266.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SHASUN PHARMA  CIPLA  ABBOTT INDIA  ALEMBIC LTD  WYETH LTD  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - PANACEA BIOTECH COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS